Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of the PTK7-Targeted Antibody-drug Conjugate DAY301 in Patients With Locally Advanced or Metastatic Solid Tumors

NCT06752681 is registered in ClinicalTrials.gov with Day One Biopharmaceuticals, Inc. as lead sponsor.

NCT NCT06752681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06752681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of the PTK7-Targeted Antibody-drug Conjugate DAY301 in Patients With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Day One Biopharmaceuticals, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
November 18, 2024
Completion date
December 31, 2028
Enrollment
300 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors